Showing 2,669 results

Filters Content type: News, Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

Pharmaceutical industry

Gilead's Sovaldi soars with sales of $3.48 billion

Editor's pick
Pharma Times
25 July 2014
Hepatitis C treatment

Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug

Editor's pick
Treatment Action Group
25 July 2014
Hepatitis C treatment

Opioid Therapy No Bar to Novel HCV Drugs

Editor's pick
MedPage Today
24 July 2014
Hepatitis C treatment

HIV, HCV and TB Pipeline Report

Editor's pick
Treatment Action Group & i-Base
21 July 2014
Hepatitis C treatment

AbbVie 3D regimen cures most genotype 1 HCV in people with HIV and HCV co-infection

News
21 July 2014
Hepatitis C treatment

Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection

News
21 July 2014
Hepatitis C treatment

J&J beats forecasts, helped by new hepatitis C drug

Editor's pick
Reuters
16 July 2014
Hepatitis C treatment

US govt demands more pricing info on Gilead HCV pill

Editor's pick
Pharma Times
15 July 2014
Hepatitis C treatment

EU nations join forces against 'exorbitant' hepatitis C drug: France

Editor's pick
Medical Xpress
10 July 2014
Hepatitis C treatment

US: Studies look at hepatitis C care cascade and healthcare utilization

Editor's pick
HIVandHepatitis.com
8 July 2014
New & experimental hepatitis C treatment

Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen

Editor's pick
Bristol-Myers Squibb press release
8 July 2014
Hepatitis & HIV

Patients coinfected with HIV, HCV showed spontaneous HCV clearance during ART

Editor's pick
Healio
7 July 2014
New & experimental hepatitis C treatment

Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union

Editor's pick
Bristol-Myers Squibb press release
30 June 2014
Hepatitis C treatment

Fighting for their lives: Economist Intelligence Unit report finds patient groups lead global efforts to address hepatitis C

Editor's pick
Janssen press release
25 June 2014
New & experimental hepatitis C treatment

HCV drug out of the running

Editor's pick
MedPage Today
23 June 2014
New & experimental hepatitis C treatment

A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi

Editor's pick
Reuters
23 June 2014
Hepatitis C treatment

2014 UK Consensus Guidelines — Hepatitis C Management and Direct-acting Anti-viral Therapy

Editor's pick
Medscape (requires registration)
19 June 2014
New & experimental hepatitis C treatment

UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

Editor's pick
CDC
19 June 2014
New & experimental hepatitis C treatment

AbbVie all-oral hepatitis C therapy gets rapid EU review

Editor's pick
Reuters
17 June 2014
Hepatitis C treatment

NICE rejection looms for Sovaldi

Editor's pick
Pharmafile
16 June 2014
New & experimental hepatitis C treatment

NICE consults on draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

Editor's pick
NICE press release
16 June 2014
Hepatitis C treatment

Low uptake of HCV treatment in England will lead to substantial disease burden by 2035

News
13 June 2014
Pharmaceutical industry

FDA lifts hold on Achillion's hepatitis C drug, shares jump

Editor's pick
Reuters
11 June 2014
Hepatitis C treatment

Why The Hepatitis C Cost Cutters May Have Already Lost

Editor's pick
Forbes
11 June 2014